Saturday 17 October 2026
Export NKTX’s income statement to Excel — free account
Nkarta, Inc.
NKTX Healthcare Biotechnology
In the quarter to June 2026, EPS fell 74.2% and free cash flow fell 29.2%, each against the same quarter a year earlier.
1.80
0.13
−6.74%
Follow NKTX
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | 22.46 | 12.46 | 5.07 | 1.28 | 2.08 | 1.31 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | — | — | — | 79.16 | 62.71 | 20.35 | 6.84 | 16.24 | 2.74 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | 70 | 95 | 136 | 163 | 150 | 157 | 108 | ||||
| Revenue/emp, $m | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | 7 | 0 | — | — | — | — | — | — | ||||
| Gross margin, % | — | — | 0.00 | 100.00 | 0.00 | 0.00 | 0.00 | — | — | — | |||||
| EBT | — | — | 0 | (21) | (91) | (86) | (114) | (118) | (109) | (104) | |||||
| EBT margin, % | — | — | (4.19) | (18,326.96) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Net income | — | 0 | 0 | (21) | (91) | (86) | (114) | (118) | (109) | (104) | |||||
| Depreciation | — | — | 0 | 0 | 2 | 5 | 2 | (3) | 2 | 5 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | 0.20 | 0.08 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||
| Earnings | — | — | (0.01) | (14.41) | (5.44) | (2.62) | (2.61) | (2.40) | (1.60) | (1.41) | |||||
| Cash flow | — | — | (0.16) | (12.55) | (2.59) | (2.07) | (1.31) | (1.76) | (1.47) | (1.20) | |||||
| Capex | — | — | 0.00 | (1.32) | (0.45) | (0.15) | (1.08) | (0.57) | (0.06) | (0.02) | |||||
| Free cash flow | — | — | (0.16) | (13.87) | (3.04) | (2.22) | (2.39) | (2.33) | (1.53) | (1.22) | |||||
| Book value | — | — | (0.17) | (17.42) | 19.11 | 7.64 | 8.53 | 5.58 | 6.01 | 4.22 | |||||
| Shares, m | — | — | 33 | 1 | 17 | 33 | 44 | 49 | 68 | 74 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | 0.00 | 0.00 | — | — | — | — | — | — | ||||
| P/S | — | — | 0.00 | 0.00 | — | — | — | — | — | — | |||||
| P/B | — | — | 0.00 | 0.00 | — | — | — | — | — | — | |||||
| EV/Sales | — | — | 0.00 | 0.00 | — | — | — | — | — | — | |||||
| EV/FCF | — | — | (1.67) | (1.67) | — | — | — | — | — | — | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | (5) | (18) | (44) | (68) | (57) | (86) | (100) | (89) | ||||
| Capex | — | — | (1) | (2) | (8) | (5) | (47) | (28) | (4) | (1) | |||||
| Free cash flow | — | — | (5) | (20) | (51) | (73) | (104) | (114) | (104) | (90) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | 6 | 29 | 310 | 233 | 339 | 230 | 254 | 260 | ||||
| Total debt | — | — | 13 | 67 | 9 | 12 | 83 | — | — | — | |||||
| Net debt | — | — | 5 | (37) | (315) | (238) | (352) | (248) | (267) | (276) | |||||
| Shareholders’ equity | — | — | (5) | (25) | 321 | 251 | 372 | 273 | 408 | 312 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | (5.72) | (72.65) | (47.33) | (28.15) | (30.48) | (27.59) | (24.72) | (22.99) | ||||
| ROIC | — | — | 0.00 | 0.00 | (510.42) | (419.43) | (370.55) | (327.87) | (56.98) | (211.53) | |||||
| ROE | — | — | 1.78 | 136.51 | (61.79) | (30.09) | (36.53) | (36.41) | (31.94) | (28.90) | |||||
Negative figures in brackets.
Fiscal years to Dec 2019 · latest quarter Jun 2019
Charts ten years each
Nkarta, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| MOLN Molecular Partners AG Sponsored ADR | $143.5M | — (loss-making) | — (loss-making) | −98.86% (below 0%: shrinking) | n/m | +23.77% (above 0%: growing) | 0.00% | 0.00% | Compare |
| TARA Protara Therapeutics, Inc. | $141.8M | — (loss-making) | — | — | n/m | −28.10% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| ALXO ALX Oncology Holdings Inc. | $138.3M | — (loss-making) | — (loss-making) | −100.00% (below 0%: shrinking) | n/m | +31.65% (above 0%: growing) | 0.00% | 0.00% | Compare |
| NKTX Nkarta, Inc. | $138.2M | — (loss-making) | — | — | n/m | −29.19% (below 0%: shrinking) | 0.00% | 0.00% | |
| AVXL Anavex Life Sciences Corp. | $137.2M | — (loss-making) | — | — | n/m | +27.02% (above 0%: growing) | — | 0.00% | Compare |
| KRRO Korro Bio, Inc. | $137.1M | — (loss-making) | — (loss-making) | −86.28% (below 0%: shrinking) | n/m | +12.07% (above 0%: growing) | 100.00% | 0.00% | Compare |
| ANTX AN2 Therapeutics, Inc. | $135.9M | — (loss-making) | — | — | n/m | +7.91% (above 0%: growing) | 0.00% | 0.00% | Compare |
| CUE Cue Biopharma, Inc. | $135.6M | — (loss-making) | — (loss-making) | +166.66% (above 0%: growing) | n/m | −742.65% (below 0%: shrinking) | 100.00% | (1,113.30%) | Compare |
| TLSA Tiziana Life Sciences Ltd | $134.7M | — (loss-making) | — | — | −258.11% (below 0%: shrinking) | +18.03% (above 0%: growing) | 0.00% | — | Compare |
| Median of peers | $137.1M | — | — | −92.57% | — | +15.05% | 0.00% | 0.00% |
Nkarta, Inc. (NKTX) key facts
- Nkarta, Inc. (NKTX) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- As of October 16, 2026, NKTX traded at $1.80, a market capitalization of $138.2 million.
- Return on equity was −28.9% and debt-to-equity 0.00.
Nkarta, Inc. (NKTX) Latest News
No news at this impact. Lower the threshold for more.